Bodyport Appoints Amit Rushi as Chief Commercial Officer and Phyllis Whiteley, Ph.D. as Chair of the Board of Directors
SAN FRANCISCO–(BUSINESS WIRE)–Bodyport, the digital health company focused on the detection and management of heart disease, today announced that it has named Amit Rushi as Chief Commercial Officer (CCO) and Phyllis Whiteley as Chair of the Board of Directors. With this newly created role, Amit Rushi will serve as part of the executive team and prepare the organization for commercialization and growth. As Chair of the Board, Phyllis Whiteley will help deliver strong value to Bodyport’s customers, employees, and shareholders as it accelerates its strategy.
The addition of these senior leadership members adds decades of healthcare experience to Bodyport’s executive team ahead of its anticipated commercial phase later this year. The company anticipates expanding its organization in 2021 and marks these senior leadership appointments as an important company milestone as it prepares to bring Bodyport to market.
“We are excited to welcome Phyllis to be our Chair of the Board, bringing her wealth of expertise to help guide us as we move into the next phase of our growth and Amit Rushi as our CCO, to build the commercial infrastructure and market entry for Bodyport,” said Bodyport co-founder and CEO Corey Centen. “We look forward to Amit’s leadership and insights, generated from his deep experience across many sectors of healthcare, spanning both patient-centric and clinician-facing digital health chronic disease solutions.”
Amit Rushi brings over two decades of medical device and digital health experience to Bodyport, with expertise in building and leading world-class commercial teams, a track record of successful product launches, and translating health technology innovation into market adoption and clinical impact. Before joining Bodyport, Amit served as the Vice President, Commercial at Alio, and as Vice President of Strategy, Informatics, & Business Operations at Science 37. Prior to this, Amit established the Digital Health function at Medtronic Diabetes, building the data science team to drive business and product strategy. He also served on the Board of Glooko, representing Medtronic’s corporate venture investment, and led commercial functions in the Cardiovascular Division, launching multiple products and integrating acquired companies. Amit earned both his MBA and MSIS degrees from the Questrom School of Business at Boston University and BS in business administration from the Marshall School of Business at the University of Southern California.
“I am thrilled to be joining Bodyport, to work alongside such a passionate, mission-driven, and innovative team to bring our platform to heart disease patients and their clinical teams,” said Amit Rushi. “Bodyport is pioneering an incredibly intuitive care management platform to make a meaningful difference in the quality of care for patient’s lives.”
“I’m honored to serve as the new chair of the Bodyport Board and look forward to working closely with Corey Centen, CEO and co-founder,” said Phyllis Whiteley. “This marks a pivotal new chapter for the company, and I look forward to helping Bodyport broaden its impact. I’m excited to begin collaborating with our other board members to ensure that early detection and personalized care is available to the millions of Americans living with heart disease.”
Both of these appointments reflect Bodyport’s growth and continued focus on delivering clinical outcomes to drive commercial expansion. Phyllis Whiteley Ph.D., Venture Partner of Playground Global, assumes the role of Chair of Bodyport’s Board of Directors, with other Board members including CEO and Co-Founder Corey Centen, Co-Founder Sarah Smith, Garry Tan, Managing Partner at Initialized Capital, and Debbie Lin, Executive Director at Boehringer Ingelheim Venture Fund (BIVF).
Bodyport’s mission is to prevent and ultimately eliminate heart disease by empowering every person with high-quality, actionable health information through everyday tools in their own home. Bodyport’s biomarker platform is able to provide advanced cardiac monitoring and connected care to patients to support the prevention and management of heart disease.